Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Current Investments (2022 - 2025)

Historic Cash & Current Investments for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Addex Therapeutics' Cash & Current Investments rose 4790732.56% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4790732.56%. This contributed to the annual value of $3.8 million for FY2024, which is 1159.12% down from last year.
  • Addex Therapeutics' Cash & Current Investments amounted to $2.7 million in Q3 2025, which was up 4790732.56% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Cash & Current Investments ranged from a high of $22.2 million in Q1 2022 and a low of $490.17 during Q3 2023
  • Moreover, its 4-year median value for Cash & Current Investments was $4.0 million (2025), whereas its average is $6.8 million.
  • Per our database at Business Quant, Addex Therapeutics' Cash & Current Investments plummeted by 9999.77% in 2023 and then soared by 11524471.75% in 2025.
  • Quarter analysis of 4 years shows Addex Therapeutics' Cash & Current Investments stood at $7.2 million in 2022, then crashed by 39.67% to $4.4 million in 2023, then fell by 12.31% to $3.8 million in 2024, then decreased by 28.24% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $4.0 million for Q2 2025, and $3.2 million during Q1 2025.